PICKER, Louis,HANSEN, Scott,FRUEH, Klaus,MALOULI, Daniel
申请号：
AU2020204529
公开号：
AU2020204529A1
申请日:
2020.07.07
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
#$%^&*AU2020204529A120200730.pdf#####Abstract: Disclosed herein are CMV vectors that include a heterologous protein antigen, an active ULI 31 protein ( or an ortho -log thereof), an active UL128 protein (or an ortholog thereof), but wherein the CMV vector lacks an active UL130 protein (or an or-tholog thereof). Also disclosed herein are CMV vectors comprising: a heterologous protein antigen, an active ULI 31 protein ( or an ortholog thereof), an active UL130 protein (or an ortholog thereof), but wherein the CMV vector lacks an active UL128 protein. Further disclosed are methods of using CMV vectors to generate an immune response characterized as having at least 10% of the CDS+ T cells directed against epitopes presented by MHC Class 11.
